title: [Medical treatment of digestive neuroendocrine tumours].
abstract: Surgery is the only therapy able to cure patients with digestive neuroendocrine tumor. However, due to the presence of diffuse metastases, radical surgery is often not feasible. In these cases, medical treatment plays a critical role, because of its ability to control symptoms in functioning tumors and to inhibit tumor growth. Different therapeutic approaches, such as chemotherapy, hepatic artery chemoembolization and targeted radio-nuclide therapy can be used alone or combined to the biologic treatment with somatostatin analogues and interferon. However, an accurate staging by imaging procedures plus a histological, immunohistochemical and biomolecular examination must be performed before planning an optimal medical treatment.
authors.affiliation: Cattedra di Gastroenterologia, II Facoltà di Medicina e Chirurgia, Università La Sapienza, Rome, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Panzuto
authors.forename: S
authors.initials: S
authors.lastname: Nasoni
authors.forename: G
authors.initials: G
authors.lastname: Delle Fave
mesh_terms: D000465:Algorithms; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D002454:Cell Differentiation; D003131:Combined Modality Therapy; D004067:Digestive System Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D004621:Embolization, Therapeutic; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use; D009363:Neoplasm Proteins / Q000187:drug effects; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000187:drug effects; D012189:Retrospective Studies; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007205:Indium Radioisotopes; D009363:Neoplasm Proteins; D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; C060347:lanreotide; C071632:SDZ 215-811; D013004:Somatostatin; D004369:Pentetic Acid; D015282:Octreotide